Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose (GIP-GLP-gas)

This study has been completed.
Karolinska Institutet
University of Copenhagen
Information provided by:
Uppsala University Identifier:
First received: March 2, 2010
Last updated: NA
Last verified: July 2009
History: No changes posted
Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin hormones not only stimulate insulin release but also inhibits gastric emptying. This effect can be utilized for further drug development.

Condition Intervention Phase
Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Effects of GIP and GLP-1 on Gastric Emptying, Appetite and Insulin-glucose Homeostasis

Resource links provided by NLM:

Further study details as provided by Uppsala University:

Primary Outcome Measures:
  • Gastric emptying rate [ Time Frame: 2005-2006 ]

Secondary Outcome Measures:
  • Plasma glucose, insulin release, appetite [ Time Frame: 2005-2006 ]

Enrollment: 15
Study Start Date: August 2006
Study Completion Date: November 2009
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GIP two doses and GLP-1 one dose
Intervention with infusion of GIP or GLP-1 intravenously
Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Other Names:
  • GIP
  • GLP-1
  • Saline
Placebo Comparator: Saline infusion
Other: Glucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Other Names:
  • GIP
  • GLP-1
  • Saline

Detailed Description:
Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under simultaneous gastric emptying study and appetite questionnaires and blood sampling for analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as well as those administered, GIP and GLP-1.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women
  • 18-50 years old;
  • otherwise healthy and HIV and HCB, HCV negative

Exclusion Criteria:

  • Age >50,
  • all types of diseases and drug users.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01079624

Karolinska University Hospital
Stockholm, Sweden, 17176
Sponsors and Collaborators
Uppsala University
Karolinska Institutet
University of Copenhagen
Principal Investigator: Per M Hellstrom, MD, PhD Karolinska Institutet, Uppsala University
  More Information

Responsible Party: Professor Per Hellström, Uppsala University Identifier: NCT01079624     History of Changes
Other Study ID Numbers: GIP/GLP-gastric empt-APP-hor
K2010-55X -07916-24-3 ( Other Grant/Funding Number: Swedish Research Council )
Study First Received: March 2, 2010
Last Updated: March 2, 2010

Keywords provided by Uppsala University:
Incretin hormones
Glucose-insulinotropic peptide
Glucagon-like peptide-1
Gastric emptying
Glucose disposal
Gut hormones

Additional relevant MeSH terms:
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on May 25, 2017